Publication Date:
2021
Short description:
Evidence-based Definition for Extensively Drug-resistant Tuberculosis / Roelens, M., Migliori, G.B., Rozanova, L., Estill, J., Campbell, J.R., Cegielski, J.P., Tiberi, S., Palmero, D., Fox, G.J., Guglielmetti, L., Sotgiu, G., Brust, J.C.M., Bang, D., Lienhardt, C., Lange, C., Menzies, D., Keiser, O., Raviglione, M.. - In: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. - ISSN 1073-449X. - (2021). [10.1164/rccm.202009-3527OC]
abstract:
Until 2020, extensively drug-resistant tuberculosis (XDR-TB) was defined as resistance to rifampicin and isoniazid (multidrug-resistant tuberculosis, MDR-TB), any fluoroquinolone (FQ) and any second-line injectable drug (SLID). In 2019 the World Health Organization issued new recommendations for managing patients with drug-resistant tuberculosis, substantially limiting the role of SLID in MDR-TB treatment and thus putting that XDR-TB definition into question.
Iris type:
1.1 Articolo in rivista
Keywords:
Drug resistance; Epidemiology; Meta-analysis; Tuberculosis
List of contributors:
Roelens, M.; Migliori, G. B.; Rozanova, L.; Estill, J.; Campbell, J. R.; Cegielski, J. P.; Tiberi, S.; Palmero, D.; Fox, G. J.; Guglielmetti, L.; Sotgiu, G.; Brust, J. C. M.; Bang, D.; Lienhardt, C.; Lange, C.; Menzies, D.; Keiser, O.; Raviglione, M.
Published in: